<SEC-DOCUMENT>0001193125-18-351181.txt : 20181218
<SEC-HEADER>0001193125-18-351181.hdr.sgml : 20181218
<ACCEPTANCE-DATETIME>20181217181259
ACCESSION NUMBER:		0001193125-18-351181
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20181217
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20181218
DATE AS OF CHANGE:		20181217

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FIBROGEN INC
		CENTRAL INDEX KEY:			0000921299
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36740
		FILM NUMBER:		181239029

	BUSINESS ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		415-978-1200

	MAIL ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d653395d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): December 17, 2018 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>FibroGen, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-36740</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">77-0357827</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FibroGen, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>409 Illinois Street </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>San
Francisco, CA 94158 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(415) <FONT STYLE="white-space:nowrap">978-1200</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
name or former address, if changed since last report.) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT
STYLE="white-space:nowrap">Rule&nbsp;14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT
STYLE="white-space:nowrap">Rule&nbsp;13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this
chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other Events </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December 17, 2018, FibroGen, Inc. announced that its subsidiary, FibroGen (China) Medical Technology Development Co., Ltd., received
marketing authorization from the National Medical Products Administration in China for roxadustat, a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> hypoxia-inducible factor prolyl hydroxylase
inhibitor, for the treatment of anemia caused by chronic kidney disease in patients on dialysis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A copy of such press release is
furnished as Exhibit&nbsp;99.1 to this report and is incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements and Exhibits. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit</B><br><B>No.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d653395dex991.htm">Press Release titled &#147;FibroGen Announces Approval of Roxadustat in China for the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis &#148; dated December 17, 2018 </A></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>FIBROGEN, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: December 17, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Lowenstein</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Michael Lowenstein</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Legal Officer</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d653395dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g653395g1217115612142.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FibroGen Announces Approval of Roxadustat in China for the Treatment of </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Anemia in Chronic Kidney Disease Patients on Dialysis </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>China is the First Country to Approve Roxadustat </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">First-in-Class</FONT></FONT> Roxadustat Offers a New, Effective Oral
Treatment </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SAN FRANCISCO, December&nbsp;17, 2018 &#150; FibroGen, Inc. (NASDAQ:FGEN) today announced that FibroGen (China) Medical Technology
Development Co., Ltd. (FibroGen China) has received marketing authorization from the National Medical Products Administration (NMPA) for roxadustat, a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT>
hypoxia-inducible factor prolyl hydroxylase inhibitor <FONT STYLE="white-space:nowrap">(HIF-PHI)</FONT> for the treatment of patients with anemia caused by chronic kidney disease (CKD) in patients who are dialysis-dependent (DD). The medicine can be
prescribed to patients who use hemodialysis or peritoneal dialysis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Anemia caused by CKD is associated with cardiovascular disease, hospitalization,
cognitive impairment, and reduced quality of life, and has been shown consistently to increase the mortality risk in patients with CKD.<SUP STYLE="font-size:85%; vertical-align:top">1</SUP> Anemia becomes increasingly common among individuals with
CKD as their disease progresses, affecting nearly all patients at the dialysis-eligible stage.<SUP STYLE="font-size:85%; vertical-align:top">1</SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thomas B. Neff, Chief Executive Officer, FibroGen, said: &#147;We believe roxadustat will make a significant difference for patients in China by addressing a
substantial unmet medical need in the treatment of anemia associated with chronic kidney disease. This is an exciting milestone, as we are realizing our decade-long commitment to bringing innovative medicine to people in China. We look forward to
bringing roxadustat to patients worldwide.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Chung, Managing Director, FibroGen China, said: &#147;We are grateful to the patients and
physicians in China who participated in our clinical studies. Almost ten years ago, FibroGen made the decision to develop roxadustat, a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> investigational
candidate, in China as a Domestic Class&nbsp;1 Innovative Drug. It arose out of a commitment to give Chinese patients accelerated access to critically needed innovative medicines.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roxadustat (China Approved Drug Name: <FONT STYLE="font-family:pmingliu; font-size:9pt">&#32599;&#27801;&#21496;&#20182;</FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt">; Chinese brand name: </FONT><FONT STYLE="font-family:pmingliu; font-size:9pt">&#29233;&#29790;&#21331;</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt"><SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) is the first approved oral <FONT STYLE="white-space:nowrap">HIF-PHI</FONT> medicine. This approval is supported by an open-label, active-control <FONT STYLE="white-space:nowrap">26-week</FONT>
Phase 3 trial in <FONT STYLE="white-space:nowrap">DD-CKD</FONT> patients with anemia who were previously treated with various forms of locally manufactured injectable recombinant erythropoietin products. In the trial, these <FONT
STYLE="white-space:nowrap">DD-CKD</FONT> patients were then randomized to receive either roxadustat or ESPO<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
(</FONT><FONT STYLE="font-family:pmingliu; font-size:9pt">&#21033;&#34880;&#23453;</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt"><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) brand epoetin alfa, manufactured and
marketed by Kyowa Hakko Kirin. </FONT></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FibroGen China has also completed a roxadustat China Phase 3 placebo-controlled trial in <FONT
STYLE="white-space:nowrap">non-dialysis-dependent</FONT> (NDD) CKD patients. The addition of NDD patients to the label is expected once regulatory inspections of the clinical trial sites by the NMPA are completed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Anemia commonly develops in association with CKD. Based on a large-scale cross-sectional survey performed between September 2009 and September 2010 and
published in the <I>Lancet</I>, there are an estimated 120&nbsp;million CKD patients in China, including estimated 0.5&nbsp;million patients on dialysis who may be suffering from anemia, a number that is increasing significantly.<SUP
STYLE="font-size:85%; vertical-align:top">2,3</SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AstraZeneca and FibroGen China are collaborating on the development and commercialization of
roxadustat in China. FibroGen China, based in Beijing, is a subsidiary of FibroGen, Inc. that sponsored the development and registration of roxadustat as a Domestic Class&nbsp;1 Innovative Drug. FibroGen China conducted the China Phase 3 clinical
trials and submitted the New Drug Application for registration of roxadustat to the Chinese regulatory authorities. Following this approval, AstraZeneca will manage commercialization activities in China, and FibroGen China will manage commercial
manufacturing and medical affairs as well as continued clinical development and regulatory affairs. AstraZeneca and FibroGen expect to launch roxadustat in China in the second half of 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Roxadustat </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roxadustat <FONT
STYLE="white-space:nowrap">(FG-4592),</FONT> discovered by FibroGen, is a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class,</FONT></FONT> orally administered small molecule currently approved in China for the
treatment of patients with anemia from CKD on dialysis. Roxadustat is a <FONT STYLE="white-space:nowrap">HIF-PHI</FONT> that promotes erythropoiesis through increasing endogenous production of erythropoietin, improving iron regulation, and
overcoming the negative impact of inflammation on hemoglobin syntheses and red blood cell production by downregulating hepcidin. Administration of roxadustat has been shown to induce coordinated erythropoiesis, increasing red blood cell count while
maintaining plasma erythropoietin levels within or near normal physiologic range in multiple subpopulations of CKD patients, including in the presence of inflammation and without a need for supplemental intravenous iron.&nbsp;Roxadustat was well
tolerated in the China Phase 3 studies. The adverse events observed were consistent with underlying diseases in patients with CKD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FibroGen, the
originator, and AstraZeneca are collaborating on the development and commercialization of roxadustat for the treatment of anemia in the U.S., China, and other markets in the Americas, Australia, New Zealand and Southeast Asia. FibroGen and Astellas
Pharma Inc. and FibroGen are collaborating on the development and commercialization of roxadustat for the treatment of anemia in territories including Japan, Europe, the Commonwealth of Independent States, the Middle East, and South Africa. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Anemia Associated with CKD in China</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Anemia
commonly develops in association with chronic kidney disease and is linked to significant morbidity and mortality in both the dialysis and <FONT STYLE="white-space:nowrap">non-dialysis</FONT> populations. Although CKD may occur at any age, it is
more common in aging populations, and its prevalence is increasing. CKD can be both a cause and a consequence of cardiovascular disease and is a critical healthcare issue. There is no treatment available that is curative, or has the ability to stop
kidney deterioration.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About FibroGen</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FibroGen, Inc.,
headquartered in San Francisco, California, with subsidiary offices in Beijing and Shanghai, People&#146;s Republic of China, is a leading biopharmaceutical company discovering and developing a pipeline of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class</FONT></FONT> therapeutics.&nbsp;The company applies its pioneering expertise in hypoxia-inducible factor (HIF), connective tissue growth factor (CTGF) biology, and clinical development to advance innovative
medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the company&#146;s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity, completing worldwide Phase 3 clinical
development for the treatment of anemia in chronic kidney disease (CKD), with a New Drug Application (NDA) now approved by the </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Page 2 of 3
</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
National Medical Products Administration (NMPA) in China. Our partner Astellas submitted a NDA for the treatment of anemia in CKD patients on dialysis in Japan and currently under review by the
Pharmaceuticals and Medical Devices Agency (PMDA). Roxadustat is in Phase 3 clinical development in the U.S. and Europe and in Phase 2/3 development in China for anemia associated with myelodysplastic syndromes (MDS).&nbsp;Pamrevlumab, an anti-CTGF
human monoclonal antibody, is advancing towards Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and pancreatic cancer, and is currently in a Phase 2 trial for Duchenne muscular dystrophy (DMD). FibroGen is also
developing a biosynthetic cornea in China. For more information, please visit <U>www.fibrogen.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This release contains forward-looking statements regarding our strategy, future plans and prospects, including statements regarding the development of the
company&#146;s product candidates pamrevlumab and roxadustat, the potential safety and efficacy profile of our product candidates, and our clinical, regulatory plans, and those of our partners. These forward-looking statements include, but are not
limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as &#147;may,&#148; &#147;will&#148;, &#147;should,&#148; &#147;on track,&#148;
&#147;could,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;predict,&#148; &#147;potential,&#148; &#147;continue&#148; and similar words, although some forward-looking statements
are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of our various programs, including the
enrollment and results from ongoing and potential future clinical trials, and other matters that are described in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2017, and our
Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the fiscal quarter ended September&nbsp;30, 2018 filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned
not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:pmingliu; font-size:9pt">&#29233;&#29790;&#21331;</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt"><SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> is a registered trademark of FibroGen, Inc. </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>References </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Babitt JL, Lin HY. Mechanisms of Anemia in CKD. J Am Soc Nephrol (2012); 23:1631-1634. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey.
<I>Lancet</I> 2012; 379: 815&#150;22. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">China National Renal Data System (CNRDS), 2016. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"># # # </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FibroGen, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Karen L. Bergman </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President, Investor Relations and Corporate Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1 (415) <FONT STYLE="white-space:nowrap">978-1433</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>kbergman@fibrogen.com </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Page 3 of 3 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g653395g1217115612142.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g653395g1217115612142.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !0 2\# 2(  A$! Q$!_\0
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MB2ABC!MK%3CL1U%(H?1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)'N:*/YB#C)Z?UJWI22)I=OYP F9-\@ _B;D_J:P9Q;+I5O8V]HRK<7'E%E
M)9%8E\?@I'XUO37X1%6.-S._$:,,9/O[#O4M%PES2]"[4,MU;P,%FGBC8C(#
MN!G\Z?&'$2B1@SX&X@8!->*_&EB/$FG88C_0ST/^V:(1YG8TD[*Y[)_:-C_S
M^6__ ']7_&C^T;'_ )_+?_OZO^->"V?PP\2WUC;WD)M_*GC65,S'.&&1_.I_
M^%3>*O6V_P"_Y_PK3V<?YB>9]CWA)XI(O-25&C_O*P(_.ECECE0/&ZNAZ,IR
M#7FS>$-?M_A0VAPNHU 3-(RQR?ZQ-Y.W/N*O_"W0=8T+2+Q-6#1B:4-# S9*
M #D^V>/RJ'%6;N5=W.WCN[:63RXKB)W_ +JN":FKP7X6DGXD-EB?W5QU/N*]
MZHG'E=A1=T%%%%04%%%% !1110 4C.J*6=@J@9))P!4=Q/%:V\EQ.X2*)2[L
M3P .2:\!\3^,=7\;:P+#3A,MF[[+>VC.#)_M-_GBKA!R)E*Q[5+XM\/0R&.3
M6+,,#@CS0:O66IV.I1^997<-POK&X;%>0V/P7OYK97O-2A@E/)C1-V/QKG=9
M\-^(? %[#=QSLL9;$=U;DX)_ND?TJ_9Q>B8N9K='T7161X8O]0U+P_:7>J6G
MV6[D7+Q^OH<=L]<5KUB]"PHHHH **** "BBB@ HHHH **** &N6$;% "V#M!
MZ9JB-6@CE\B\/V:;&?GX4]>AZ=JT*BN+:"[A:*XB26,]589%-6)DGT,*6\N?
M.DGTN(BU?_6RR+\H/]]1U/O6%I^FQWOB&VM3(;B"T9Y][\^9&2#'@= N[(XZ
M[:VWLKQ7DM]+G+V:8\R*5N"?[BMV]ZQ-/U,6?BM;AHC;VDQ-D(WZ1!2,8/0C
M?N'MFK7D85)IVC+2[._J*YMH;NVDM[B-9(I%*LK#@@U)G-1W-S#:6TEQ.X2*
M-2S,3T K,Z':VIP.DQ2V=_/&MSY4NFEX4RI9)F)SC'9MFSIZUTEMJ!M;DRZS
M%]FN)/D23.8@.R@]C7-Z4USJ%WYZ0,K:@TDBM(2J12@\,/5MF!_P&NHL;)9+
MAAJ;?:+Z/GY_N;>S*O3%:2>NIA2A:-XZ7-E75U#*P93R"#D&O$_C7_R,FG?]
M>9_]#->OPZ6EI*&LY&A0MEHNJGZ#M7D'QJX\2:<?^G,_^AFG2^,TDWRZG>^'
M_%_AZV\-Z7!-J]LDL=I$CJ6Y4A "*TO^$V\,_P#09M?^^J\VTSX/?VCI5G??
MVML^TP)+M\KIN4''ZU;_ .%)?]1G_P A4W&G?<=Y=CK_ !QK+Q_#^ZU32;PJ
M6$;13Q'J"X'%9_PHU;4-8T"]FU&[DN9$NBBM(<D#:IQ47C#2O[#^#\FF>;YO
MV:.*/?C&[$BU7^"W_(LW_P#U^'_T!:5E[-AKS'F&@:^_AKQ#=ZE%&))@DT<0
M/3<S<$^U=*VG_$G68O[1+W@5AN5!)L./9:Q? ]M;7?Q&L8;L*8OM$C!6Z,P#
M%1^8%?1]:5)<KV)BKH\3\*?$?5]*UE-+\1,\D#2>4[S#$D+'@$^HKH/BYKFI
MZ,FD'3;V6V\TR[_+.-V N/YFN8^-%O!%XEM)8@JS2VA,N.^&(!/Z_E5KXK.\
MF@>$WDSYC0,6SZ[(\TDDW&7<+M)HSO[<\;^,8(8],%T8;6)(Y'B.W>X'+$]R
M?2ND37]4\ >"XSJ\TMUK5](QAMYGW"%1QD_S^IKL? %M%;>!='6) N^W61L=
MV;DG]:\K^+LDDOCJ*&8E84MHU4_[)8[C_GTI)J4N6V@WHKC;7_A87BV,W]O/
M=>02=K!_+0_[HJWI'C_Q%X5U@6'B1998 0)%E'SH/[RGN*]JM((;6SA@ME58
M8T"H%Z  <5Y=\;+:W^PZ3=;0+GSFBSW*;<_H0/SHC)2?*T#32O<VOBGJHB\
M%K:4%+^2.-64_>0_,?S KFO@MI4,MQJ6JR*&DAVP19_AR,L?Y4:E:3:E\!M-
MGP7>T(ESW"*[)^BG]*C^#.LPVU[?Z1,X5[G;-#G^(J,,/KC!_ T6M3:07]Y'
ML<LL<$+S2L$CC4L['H .2:P)O%?A6YC"3ZI92)D,%<Y&0<@UL:C:?;],N[/=
ML^T0O%NQTW*1G]:\*\8_#D>$M%CO_P"T/M&Z98=GEXZ@G/Z5$(QD]65)M;'N
M-IJ^GW]E)>6EW%+;19#R*>%P,G]*\=U;QSXC\7ZR^G>'!+%;DD(L7#NO]YCV
M%6?"\DD/P1\1/$2&\V49'H50'],UR_@RZ\3637DOANT\YF"K,PC#%1R0/;O^
M5:1@E=D.3=C>N?#GQ$T:W_M!;V>38-[+%/O8?AWKM/AQXYD\3P36-^%&H6ZA
MMRC E3IG'J#U^M<S_;OQ0_Z!LG_@.*K_  ^\/>(=/\>0WU[ID]O!(LWFN5PH
MW G'YXHDKQ=[ G9Z%2Y\?:SHGCO46ENIKFS@N9XUM6;Y>X4?@<5+=)\2]8A_
MM3_2HHC\Z11ML('LM9]A9Q7_ ,9GMYU#1G4Y7*D9!VEF _,"OH&E.2C:R'%-
MGDGP]^(=_<ZNFAZXYD:4E(9G&&#C^%OK7K=> ^,HUTWXN[[8!";JVFP/[QVY
MKWZHJ):-=1Q;V84445F6%%%% !4%TL[Q>7 P1F."_P#='<CWJ>B@#+OHX--T
MJXGCWIY41*A6ZGM^)/\ .L>YMK&+3K/3+JZ\Q?**2Q)AV9B.2!USG)K9U>#[
M8UI9''ER3!Y03U1/FQ^>VDGBM=.^SBVME\P/E(H@ S\$?CUZU2=D8N*E)G(V
M<FL6-M(Z7<L$$;".7[0-_EN!SA>N#E2/3-+/::E=ZA;Q:L9[K(69UMR"J(/]
MCU+8]> :Z&6'^S]6CU2\9"DX,4I'W83_  '\LJ3[BFZ5%/:PR:H(2T=V3(T.
M"7CC_@"_AR1ZL<57-U(E27PI_P##%66[M)M*CGCN6%U:/YXB)VG@DL,>ZEA^
M-;[6:2(DD$A616WI)G/7J/H:;%:6EYI\*S1Q7*A -S*#38])2V#_ &.XG@W=
M%+;U'T!_QJ6T:14EN:->(_&H$^(].PI/^AGH/]LU[=44MK;SL&F@BD8# +H#
MC\Z(2Y7<TDKJQG^&/^13T?\ Z\H?_0!6K2*JHH50%4#  ' I:EC./^* )^'V
MHX!/,?3_ *Z+6+\%P1X:O\@C_3#U'^PM>D21QRH4D170]589!IL4$4"E88DC
M4G)"*!_*KYO=Y2;:W/F+3=/U*]UJX.F+(+NV,ERFT'=\C=O?FNX@^,NJ6]IY
M%UI4;W:C:9"Q4$^XQ7L<=I;0OOBMXD<_Q*@!J";2--N)3+/I]K)(>K/"I)_'
M%6ZB>Z$H-;,\+TC1M:^(WBC[?J"N+4L#/,5PJH/X%_S[UTOQKC"PZ$D:':IF
M  '082O6HXTBC"1HJ(.BJ, 4R6W@GQYT,<FWIO4''YTO:>\GV#DTL8O@CCP/
MHF?^?./^5<Q\4O!MQKUM#JFG1^9=VJ%)(AUDCZ\>X.?SKT5$6- B*%51@*!@
M"EJ%)J5T4U=6/#=$^*VJZ'I\>G7]A]I: !$=V*. .S>M9ES+XA^)_B"(+ 4A
M3Y5P#Y<"D\DGN:]YN-*TZZD\RXL+:5_[SQ*3^9%3P6\-M'Y<$,<2#HJ*%'Z5
M?M$M4M2>5[-E2RT>TLM"AT=8P]K' ("K#[RXP<_6O#?%7@/5O"NHF\TY9I;%
M7WPSQ??B]FQZ>M?05! (P1UJ8S<6-Q3/![#XN^(+. 17,,%T5& [@JWXUDZU
MXI\0^.)(;-XC(@<,EO;QG!;ID_G7OTFAZ3*Y>33+1F)R285S_*K%M86=EQ:V
ML$&>OEQA?Y5?M(K5(7*^K.0\#>$[C3? ]QI.KHH:]>1I(P<E%=0N#[\5YI'_
M ,)#\+O$,Q6$R6[_ "[B#Y<Z \'/8U]!5'-!%<1F.:))$/574$'\#4JIJ[]1
MN/8\@G^-5R\!6VT=5F(X+29 /T[UVW@#7-9US17FUBR:&1&Q',5VB8'N![=*
MWDT32HG#QZ99JPZ$0+D?I5_I2E*+5D@2?5G@^AJW_"[F.TX_M"XYQ[/7O%0B
MTMEE\U;>(29SO"#.?K4U$Y<P15CP7X@JQ^+ (4D>9:\X_P!VO>JA>TMI)/,D
MMXGD_O,@)_.IJ)2NDNP)6"BBBH*"BBB@ HHHH 88T,HD*C> 5!]C_P#JH\I/
M-\W8/,*[=V.<>E/HH S-5B^WF+3@PV2,))QZQ@]/Q.!],UI8Q1@9S2T$J-FV
M11VT4,TDD8VF0Y< \$^N/6I:**"@HHHH **** "BBB@ HHHH **** "BBB@
BHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
